Article PDF
Avoid common mistakes on your manuscript.
References
Rubin BP, Fletcher JA, Fletcher CD. Molecular insights into the histogenesis and pathogenesis ofgastrointestinal stromal tumors. Int J SurgPathol 2000;8:5.
Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1.
Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances inunderstanding of their biology. Hum Pathol 1999;30:1213.
Reith JD, Goldblum JR, Lyles RH, et al. Extragastrointestinal (soft tissue) stromal tumors: Ananalysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000;13:577.
Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof ofconcept and therapeutic implications. Am J SurgPathol 2004;28:889.
Atlas of Tumor Pathology: Tumors of the esophagus and stomach. Electronic fascicle v2.0b, Armed Forces Institute of Pathology, Washington DC.
Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumors. J Clin Pathol 2001;54:96.
Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577.
Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118.
Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004;28:889.
Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708.
Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660.
Gasparotto D, Rossi S, Polano M, et al. Quadruple-negative gist is a sentinel for unrecognized neurofibromatosis type 1 syndrome. Clin Cancer Res 2017;23:273.
Boikos SA, Pappo AS, Killian JK, et al. Molecular Subtypes of KIT/PDGFRA Wild-Type gastrointestinal stromal tumors: A report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol 2016;2:922.
Wang JH, Lasota J, Miettinen M. Succinate dehydrogenase subunit B (SDHB) is expressed in neurofibromatosis 1-Associated gastrointestinal stromal tumors (Gists): Implications for the SDHB Expression based classification of Gists. J Cancer 2011;2:90.
Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52.
Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum:a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006;30:477.
Casali PG, Jost L, Reichardt P, et al. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20 Suppl 4:64.
Giuliano K, Nagarajan N, Canner J, et al. Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ? J Surg Oncol 2017;115:351.
Everett M, Gutman H. Surgical management of gastrointestinal stromal tumors: analysis of outcome with respect to surgical margins and technique. J Surg Oncol 2008;98:588.
Demetri GD, Benjamin RS, Blanke CD, et al. NCCN task force report: optimal management of patients with gastrointestinal stromal tumor (GIST)-Update of NCCN Clinical Practice Guidelines. J Natl Comp Cancer Net 2007;5(2 suppl):S–1.
DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51.
Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620.
Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumor: A randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097.
Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial. JAMA 2012;307:1265.
ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23 Suppl 7:vii49.
von Mehren M, Watson JC. Perioperative tyrosine kinase inhibitors for GIST: standard... or an idea that needs further investigation? Oncology (Williston Park) 2009;23:65.
Gronchi A, Raut CP. The combination of surgery and imatinib in GIST: A reality for localized tumors at high risk, an open issue for metastatic ones. Ann Surg Oncol 2012;19:1051.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Xynogalos, S., Nomikos, I.N. Current concepts on GIST. Hellenic J Surg 89, 68–70 (2017). https://doi.org/10.1007/s13126-017-0385-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13126-017-0385-3